Clinical Research Papers:
Intravascular emboli is an independent risk factor for the prognosis of stage III colorectal cancer patients after radical surgery
Metrics: PDF 1749 views | HTML 2082 views | ?
Abstract
Qian Pei1, Hong Zhu2, Fengbo Tan1, Nanhui Yu1, Zhongyi Zhou1, Yuan Zhou1, Xiangping Song1, Yuqiang Li1, Yiming Tao3, Sai Zhang4, Liling Li5, Qingling Li5 and Haiping Pei1
1 Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, China
2 Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
3 Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China
4 Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, China
5 Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
Correspondence to:
Haiping Pei, email:
Keywords: intravascular emboli, stage III colorectal cancer, prognosis, clinicopathological characteristics, CD133
Received: April 18, 2016 Accepted: July 28, 2016 Published: August 12, 2016
Abstract
Lymphovascular emboli is a prognostic factor in stage II CRC, but the significance of intravascular emboli (IVE) in stage III is unclear. Data from consecutive stage III CRC patients receiving radical surgery between January 2009 and November 2014 were retrospectively collected. The expression of CD133 was tested by immumohistochemical (IHC) staining. The potential prognosis risk factors were tested using univariate and multivariate survival analyses. IVE was significantly associated with CD133 expression (P < 0.001), gross tumor morphology (P = 0.001), histologic type (p < 0.001), lymph node status (pN) (p < 0.001), sub-class of stage III (p = 0.001), and serum CA199 level (p = 0.022). IVE, CD133 expression and lymph node status (pN) were independent risk factors for overall survival (OS) (p < 0.001, p = 0.003, and p = 0.008, respectively) and disease-free survival (DFS) (p < 0.001, p = 0.004, and p = 0.007, respectively) in stage III CRC. IVE might be an independent risk factor for the prognosis of stage III CRC patients after radical surgery. IVE might express a cancer stem cell (CSC) phenotype.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11266